Go Pro
→ Universal Basic Income ALREADY exists (From Freedom Financial) (Ad)tc pixel Free ALLR Stock Alerts

Allarity Therapeutics (ALLR) Financials

Allarity Therapeutics logo
$1.19 -0.03 (-2.46%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$1.12 -0.06 (-5.46%)
As of 07/24/2026 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Allarity Therapeutics

Annual Income Statements for Allarity Therapeutics

This table shows Allarity Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -6.60 -27 -21 -20 -25 -11
Consolidated Net Income / (Loss)		 -13 -27 -16 -12 -25 -11
Net Income / (Loss) Continuing Operations		 -4.72 -27 -15 -12 -25 -11
Total Pre-Tax Income 		-4.52 -27 -18 -12 -25 -11
Total Operating Income		 -8.32 -27 -34 -17 -27 -13
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.32
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.32
Operating Revenue		 - - - - 0.00 0.32
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 8.32 27 34 17 27 13
Selling, General & Admin Expense		 4.10 12 9.96 10 11 6.32
Research & Development Expense		 4.22 14 6.93 7.10 6.10 6.60
Impairment Charge		 - - 18 0.00 9.70 0.00
Total Other Income / (Expense), net		 3.80 0.04 17 5.31 2.35 1.37
Interest Expense		 0.43 1.35 0.22 0.50 0.65 0.19
Interest & Investment Income		 0.71 -0.50 1.70 0.02 0.53 0.80
Other Income / (Expense), net		 3.52 1.52 16 5.79 2.47 0.76
Income Tax Expense		 0.20 0.13 -1.52 0.08 -0.38 0.00
Preferred Stock Dividends Declared		 - - 5.79 8.52 0.64 0.00
Basic Earnings per Share		 ($2.03) ($4.19) ($3,093.42) ($6,031.31) ($15.65) ($0.78)
Weighted Average Basic Shares Outstanding		 3.26M 6.36M 6.81K 3.39K 1.61M 14.38M
Weighted Average Diluted Shares Outstanding		 - - 30M 6.18M 17.01M 15.82M
Weighted Average Basic & Diluted Shares Outstanding		 - - 30M 6.18M 17.01M 15.82M

Quarterly Income Statements for Allarity Therapeutics

This table shows Allarity Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -5.55 -1.72 -3.88 -1.67 -12 -7.45 -3.01 -2.32 -2.81 -3.37 -2.81
Consolidated Net Income / (Loss)		 -4.45 -1.72 -3.84 -1.63 -12 -7.45 -2.73 -2.32 -2.81 -3.37 -2.75
Net Income / (Loss) Continuing Operations		 -4.45 -1.72 -3.84 -1.63 -12 -7.45 -2.73 -2.32 -2.81 -3.37 -2.75
Total Pre-Tax Income 		-4.45 -1.64 -3.85 -1.63 -12 -7.45 -2.73 -2.32 -2.81 -3.37 -2.75
Total Operating Income		 -4.43 -4.88 -4.24 -3.37 -12 -7.32 -3.04 -4.13 -2.52 -2.92 -2.69
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.32 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.32 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 4.43 4.88 4.24 3.37 12 7.32 3.04 4.13 2.52 3.24 2.71
Selling, General & Admin Expense		 2.48 2.26 2.07 2.31 1.59 5.47 1.63 1.81 1.32 1.56 1.42
Research & Development Expense		 1.95 2.62 2.17 1.06 1.02 1.85 1.40 2.32 1.20 1.67 1.30
Total Other Income / (Expense), net		 -0.02 3.24 0.39 1.74 0.35 -0.14 0.30 1.81 -0.29 -0.46 -0.06
Interest Expense		 0.03 0.23 0.10 0.43 0.05 0.08 0.06 0.01 0.06 0.06 0.23
Interest & Investment Income		 0.01 0.00 0.00 0.05 0.26 0.22 0.22 0.24 0.19 0.16 0.16
Other Income / (Expense), net		 0.00 3.47 0.50 2.12 0.14 -0.28 0.14 1.59 -0.42 -0.55 0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 0.00 - -0.19 -0.03 0.00 - 0.28 0.00 0.00 - 0.06
Basic Earnings per Share		 ($1,346.09) ($508.71) ($664.16) ($3.34) ($7.71) ($4.64) ($0.25) ($0.15) ($0.19) ($0.23) ($0.17)
Weighted Average Basic Shares Outstanding		 4.13K 3.39K 5.84K 499.30K 1.58M 1.61M 11.15M 15.54M 14.74M 14.38M 15.97M
Weighted Average Diluted Shares Outstanding		 4.56M 6.18M 17.61M 42.38M 4.43M 17.01M 15.08M 14.62M 15.81M 15.82M 15.91M
Weighted Average Basic & Diluted Shares Outstanding		 4.56M 6.18M 17.61M 42.38M 4.43M 17.01M 15.08M 14.62M 15.81M 15.82M 15.91M

Annual Cash Flow Statements for Allarity Therapeutics

This table details how cash moves in and out of Allarity Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -1.22 20 -17 -1.75 19 -4.18
Net Cash From Operating Activities		 -7.25 -15 -17 -13 -17 -15
Net Cash From Continuing Operating Activities		 -7.29 -15 -17 -13 -17 -15
Net Income / (Loss) Continuing Operations		 -6.62 -27 -16 -12 -25 -11
Consolidated Net Income / (Loss)		 -6.62 -27 -16 -12 -25 -11
Depreciation Expense		 0.05 0.11 0.06 0.04 0.01 -0.01
Non-Cash Adjustments To Reconcile Net Income		 -1.61 4.48 1.12 -4.33 7.74 2.10
Changes in Operating Assets and Liabilities, net		 0.89 5.83 -1.94 3.45 -0.59 -5.68
Net Cash From Investing Activities		 -0.00 1.01 0.79 0.00 -0.30 -0.01
Net Cash From Continuing Investing Activities		 -0.00 1.01 0.79 0.00 -0.30 -0.01
Purchase of Property, Plant & Equipment		 -0.00 0.00 -0.02 0.00 -0.30 -0.01
Net Cash From Financing Activities		 6.03 34 -1.31 11 37 11
Net Cash From Continuing Financing Activities		 5.95 34 0.20 11 37 11
Repayment of Debt		 -0.53 -3.03 0.00 -3.70 -1.34 0.00
Repurchase of Preferred Equity		 - 0.00 -0.80 -6.65 -3.50 0.00
Repurchase of Common Equity		 -0.22 -2.04 - - 0.00 -3.19
Issuance of Debt		 3.00 4.00 1.00 1.05 1.34 0.00
Issuance of Preferred Equity		 0.00 - 0.00 1.16 2.94 0.00
Issuance of Common Equity		 3.70 32 0.00 17 37 14
Cash Interest Paid		 0.04 0.26 0.09 0.03 0.42 0.00
Cash Interest Received		 - - - - 0.50 0.80

Quarterly Cash Flow Statements for Allarity Therapeutics

This table details how cash moves in and out of Allarity Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 1.07 -1.15 -0.02 19 -0.58 0.73 8.46 -8.05 -1.10 -3.49 15
Net Cash From Operating Activities		 -5.38 -1.67 -1.40 -7.30 -5.44 -3.21 -2.69 -5.48 -3.41 -3.24 -4.49
Net Cash From Continuing Operating Activities		 -5.38 -1.67 -1.40 -7.30 -5.44 -3.21 -2.69 -5.53 -3.36 -3.24 -4.49
Net Income / (Loss) Continuing Operations		 -4.45 -1.72 -3.84 -1.63 -12 -7.45 -2.73 -2.32 -2.81 -3.37 -2.75
Consolidated Net Income / (Loss)		 -4.45 -1.72 -3.84 -1.63 -12 -7.45 -2.73 -2.32 -2.81 -3.37 -2.75
Depreciation Expense		 0.01 0.01 0.00 0.00 0.01 0.00 0.01 0.01 -0.04 0.01 -0.03
Non-Cash Adjustments To Reconcile Net Income		 0.88 -3.53 -0.43 -2.10 9.73 0.55 0.18 0.20 0.31 1.42 0.26
Changes in Operating Assets and Liabilities, net		 -1.82 3.58 2.87 -3.57 -3.59 3.70 -0.15 -3.42 -0.82 -1.30 -1.97
Net Cash From Investing Activities		 - - 0.00 - - -0.30 0.00 - - -0.01 -0.06
Net Cash From Continuing Investing Activities		 - - 0.00 - - -0.30 0.00 - - -0.01 -0.06
Purchase of Property, Plant & Equipment		 - - - - - - 0.00 - - - -0.06
Net Cash From Financing Activities		 6.45 0.52 1.38 26 4.87 4.24 11 -2.57 2.31 -0.24 20
Net Cash From Continuing Financing Activities		 6.45 0.52 1.38 26 4.87 4.24 11 -2.57 2.31 -0.24 20
Repurchase of Common Equity		 - - - - - - 0.00 - -0.14 -0.48 -0.26
Issuance of Debt		 - - 1.34 - - - 0.00 - - - 20
Issuance of Common Equity		 10 - 0.04 28 5.43 4.24 11 - 2.45 0.24 0.00

Annual Balance Sheets for Allarity Therapeutics

This table presents Allarity Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 33 50 15 12 23 18
Total Current Assets		 1.72 21 4.97 1.97 22 18
Cash & Equivalents		 0.30 20 2.03 0.17 20 15
Restricted Cash		 - - - - - 0.00
Prepaid Expenses		 0.17 0.04 0.59 0.78 0.51 2.11
Current Deferred & Refundable Income Taxes		 0.91 0.84 0.79 0.82 0.77 0.87
Other Current Assets		 0.34 0.63 1.56 0.21 1.53 0.27
Plant, Property, & Equipment, net		 0.02 0.01 0.02 0.02 0.31 0.33
Total Noncurrent Assets		 32 28 9.56 9.87 0.00 0.00
Total Liabilities & Shareholders' Equity		 33 50 15 12 23 18
Total Liabilities		 8.96 31 13 15 11 8.43
Total Current Liabilities		 5.53 21 11 14 11 8.43
Short-Term Debt		 1.41 0.00 2.64 1.30 1.35 1.40
Accounts Payable		 2.12 0.70 6.25 8.42 4.18 4.28
Accrued Expenses		 1.84 8.59 1.90 1.31 5.23 2.67
Current Deferred & Payable Income Tax Liabilities		 0.06 0.06 0.04 0.06 0.07 0.08
Total Noncurrent Liabilities		 3.43 10 1.43 0.45 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 24 19 -0.11 -2.75 12 9.83
Total Preferred & Common Equity		 24 18 -0.11 -2.75 12 9.83
Total Common Equity		 24 18 -0.11 -4.49 12 9.83
Common Stock		 63 85 83 90 131 144
Retained Earnings		 -40 -66 -83 -94 -119 -130
Treasury Stock		 - - - - 0.00 -3.19
Accumulated Other Comprehensive Income / (Loss)		 1.38 -0.60 -0.72 -0.41 -0.35 -1.02

Quarterly Balance Sheets for Allarity Therapeutics

This table presents Allarity Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 14 12 31 20 30 21 21 35
Total Current Assets		 4.39 2.30 21 20 29 21 20 35
Cash & Equivalents		 1.40 0.31 19 18 25 18 17 20
Restricted Cash		 - - - - 2.50 - - 10
Prepaid Expenses		 0.40 0.54 0.37 0.15 0.49 1.36 1.80 3.50
Current Deferred & Refundable Income Taxes		 1.56 1.33 1.58 1.65 1.12 1.61 1.66 1.08
Other Current Assets		 1.03 0.11 0.13 0.10 0.11 0.12 0.11 0.11
Plant, Property, & Equipment, net		 0.03 0.02 0.02 0.01 0.31 0.32 0.33 0.42
Total Noncurrent Assets		 9.46 9.66 9.56 0.00 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 14 12 31 20 30 21 21 35
Total Liabilities		 17 18 11 7.41 11 9.04 8.79 28
Total Current Liabilities		 16 18 11 7.41 11 9.04 8.79 28
Short-Term Debt		 0.00 2.69 1.33 1.34 1.36 1.38 1.39 21
Accounts Payable		 6.35 11 7.75 4.69 4.35 4.61 4.60 4.24
Accrued Expenses		 1.49 1.55 1.47 1.32 5.28 2.98 2.71 2.19
Current Deferred & Payable Income Tax Liabilities		 0.03 0.04 0.06 0.06 0.08 0.08 0.08 0.08
Total Noncurrent Liabilities		 1.51 0.43 0.43 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -3.38 -6.47 20 13 19 12 12 6.92
Total Preferred & Common Equity		 -3.38 -6.47 20 13 19 12 12 6.92
Total Common Equity		 -5.12 -7.98 20 13 19 12 12 6.92
Common Stock		 88 91 120 125 141 141 144 144
Retained Earnings		 -93 -98 -100 -112 -122 -124 -127 -133
Treasury Stock		 - - - - - -2.57 -2.71 -3.45
Accumulated Other Comprehensive Income / (Loss)		 -0.76 -0.39 -0.53 -0.69 -0.63 -2.46 -2.30 -1.08

Annual Metrics And Ratios for Allarity Therapeutics

This table displays calculated financial ratios and metrics derived from Allarity Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 1.00 10,260,157.00 4,558,623.00 4,433,587.00 15,811,886.00
DEI Adjusted Shares Outstanding		 0.00 0.00 12.00 7,598.00 4,433,587.00 15,811,886.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1,754,250.00 -2,687.02 -5.67 -0.71
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -396.21% 21.85% 38.67% -119.08% 52.11%
EBIT Growth		 0.00% -421.73% 26.14% 38.67% -118.44% 52.18%
NOPAT Growth		 0.00% -219.22% -29.77% 50.30% -59.03% 53.73%
Net Income Growth		 0.00% -101.36% 39.74% 25.89% -105.99% 54.19%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 0.00% -105.30% -12.97% 24.21% -36.15% 14.59%
Free Cash Flow Firm Growth		 0.00% 0.00% -490.12% 75.64% -110.95% 18.01%
Invested Capital Growth		 0.00% -100.56% 2,626.76% -145.07% -294.06% 45.72%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -19.96% 58.68% -33.34% 25.85%
EBIT Q/Q Growth		 0.00% 0.00% -19.77% 58.59% -33.27% 25.84%
NOPAT Q/Q Growth		 0.00% 0.00% 20.70% 9.85% -9.83% 25.87%
Net Income Q/Q Growth		 0.00% 0.00% 33.39% 5.15% -30.51% 26.65%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% -14.45% 10.02% 5.73% -9.70% -0.25%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 25.23% 14.86% 6.64%
Invested Capital Q/Q Growth		 0.00% 0.00% 484.36% 55.22% -53.10% 1.00%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -3,706.25%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -3,939.06%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -3,702.19%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -3,509.69%
Tax Burden Percent		 292.85% 99.14% 91.35% 100.70% 98.47% 100.00%
Interest Burden Percent		 94.17% 107.36% 95.06% 104.20% 100.48% 94.80%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -54.15% -123.30% -155.34% 2,764.46% -541.17% -103.80%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -776.31% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -57.92%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -54.91%
Return on Common Equity (ROCE)		 -54.15% -121.50% -135.55% 14,788.74% -437.12% -103.80%
Return on Equity Simple (ROE_SIMPLE)		 -54.15% -146.80% 0.00% 432.61% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.82 -19 -24 -12 -19 -8.82
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -2,757.34%
Net Nonoperating Expense Percent (NNEP)		 645.53% -90.66% 93.64% -6.31% -63.89% -15.30%
Return On Investment Capital (ROIC_SIMPLE)		 - - - 826.35% -144.89% -78.58%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1,976.25%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 2,062.81%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 4,039.06%
Earnings before Interest and Taxes (EBIT)		 -4.80 -25 -18 -11 -25 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.75 -24 -18 -11 -25 -12
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 1.69 1.74
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 1.69 1.74
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 53.39
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 3,440.16 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 11.87
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.09 0.05 1.97 -0.47 0.11 0.14
Long-Term Debt to Equity		 0.04 0.05 0.57 0.00 0.00 0.00
Financial Leverage		 0.05 -0.41 -0.83 -3.29 -1.88 -1.45
Leverage Ratio		 1.37 1.92 3.10 -30.67 3.81 1.89
Compound Leverage Factor		 1.29 2.06 2.95 -31.96 3.83 1.79
Debt to Total Capital		 8.57% 4.95% 66.35% -89.59% 10.26% 12.47%
Short-Term Debt to Total Capital		 5.28% 0.00% 47.07% -89.59% 10.26% 12.47%
Long-Term Debt to Total Capital		 3.29% 4.95% 19.28% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 3.20% 0.00% -120.06% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 35.66% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 91.43% 91.85% -2.01% 309.65% 89.74% 87.53%
Debt to EBITDA		 -0.48 -0.04 -0.20 -0.12 -0.05 -0.12
Net Debt to EBITDA		 -0.24 0.80 -0.09 -0.10 0.73 1.12
Long-Term Debt to EBITDA		 -0.19 -0.04 -0.06 0.00 0.00 0.00
Debt to NOPAT		 -0.39 -0.05 -0.15 -0.11 -0.07 -0.16
Net Debt to NOPAT		 -0.20 1.02 -0.07 -0.09 0.95 1.51
Long-Term Debt to NOPAT		 -0.15 -0.05 -0.04 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 572.43 68.35 -9.25 -10.27
Noncontrolling Interest Sharing Ratio		 0.00% 1.46% 12.75% -434.96% 19.23% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.31 1.03 0.44 0.14 2.06 2.13
Quick Ratio		 0.05 0.96 0.18 0.01 1.80 1.74
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 7.14 -28 -6.79 -14 -12
Operating Cash Flow to CapEx		 -241,700.00% 0.00% -93,427.78% 0.00% -5,822.82% -185,250.00%
Free Cash Flow to Firm to Interest Expense		 0.00 5.30 -124.91 -13.63 -21.92 -63.44
Operating Cash Flow to Interest Expense		 -16.94 -11.05 -75.41 -25.59 -26.57 -80.11
Operating Cash Flow Less CapEx to Interest Expense		 -16.95 -10.31 -75.49 -25.59 -27.03 -80.15
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.02
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 1.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 26 -0.14 3.59 -1.62 -6.37 -3.46
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 -0.07
Increase / (Decrease) in Invested Capital		 0.00 -26 3.73 -5.21 -4.76 2.91
Enterprise Value (EV)		 0.00 0.00 12,343 2,046 1.72 3.80
Market Capitalization		 0.00 0.00 12,340 2,043 20 17
Book Value per Share		 $7.49 $2.85 ($0.01) ($0.99) $2.66 $0.62
Tangible Book Value per Share		 ($1.85) ($1.57) ($0.94) ($3.15) $2.66 $0.62
Total Capital		 27 20 5.62 -1.45 13 11
Total Debt		 2.29 0.98 3.73 1.30 1.35 1.40
Total Long-Term Debt		 0.88 0.98 1.08 0.00 0.00 0.00
Net Debt		 1.15 -19 1.70 1.13 -18 -13
Capital Expenditures (CapEx)		 0.00 -1.01 0.02 0.00 0.30 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.71 -19 -5.64 -11 -6.68 -3.79
Debt-free Net Working Capital (DFNWC)		 -2.41 0.69 -3.61 -11 13 11
Net Working Capital (NWC)		 -3.82 0.69 -6.25 -12 12 9.50
Net Nonoperating Expense (NNE)		 7.41 8.06 -8.07 -0.09 5.45 2.41
Net Nonoperating Obligations (NNO)		 1.15 -19 1.70 1.13 -18 -13
Total Depreciation and Amortization (D&A)		 0.05 1.45 0.06 0.04 0.01 -0.01
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -1,184.06%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 3,405.63%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 2,968.13%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($5,866.00) ($3,094.00) ($6,156.00) ($15.65) ($0.78)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 4.54K 6.81K 3.32K 1.61M 14.38M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 21.43K 10.30K 17.01M 15.82M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 21.43K 10.30K 17.01M 15.82M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.82 -19 -12 -12 -12 -8.82
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -2,757.34%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -3,509.69%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -11.21 -18.59 -82.92 -22.78 -37.94 -64.04
NOPAT to Interest Expense		 -13.61 -13.80 -108.18 -24.08 -29.20 -47.69
EBIT Less CapEx to Interest Expense		 -11.22 -17.84 -83.00 -22.78 -38.40 -64.08
NOPAT Less CapEx to Interest Expense		 -13.61 -13.05 -108.26 -24.08 -29.66 -47.74
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -1.69% -7.66% 0.00% 0.00% 0.00% -28.40%

Quarterly Metrics And Ratios for Allarity Therapeutics

This table displays calculated financial ratios and metrics derived from Allarity Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 2,728,823.00 4,558,623.00 4,558,623.00 4,558,623.00 4,558,623.00 4,433,587.00 17,014,737.00 15,079,572.00 14,619,636.00 15,811,886.00 15,818,980.00
DEI Adjusted Shares Outstanding		 4,548.00 7,598.00 7,598.00 7,598.00 7,598.00 4,433,587.00 17,014,737.00 15,079,572.00 14,619,636.00 15,811,886.00 15,818,980.00
DEI Earnings Per Adjusted Shares Outstanding		 -1,220.76 -226.64 -510.66 -219.66 -1,599.37 -1.68 -0.18 -0.15 -0.19 -0.21 -0.18
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 18.60% 91.96% -15.03% 43.77% -175.66% -441.41% 22.87% -101.83% 75.52% 54.44% 6.13%
EBIT Growth		 18.60% 91.91% -14.74% 43.95% -175.21% -438.03% 22.62% -102.63% 75.89% 54.34% 7.38%
NOPAT Growth		 2.98% 27.72% -15.59% 18.89% -178.20% -49.97% 28.40% -22.60% 79.55% 60.12% 11.46%
Net Income Growth		 19.25% 27.28% -14.65% 31.55% -160.63% -332.81% 28.91% -42.42% 75.79% 54.74% -0.66%
EPS Growth		 0.00% 27.28% 0.00% 0.00% 0.00% 99.09% 0.00% 0.00% 0.00% 95.04% 0.00%
Operating Cash Flow Growth		 -21.96% 31.64% 56.29% -192.63% -1.25% -91.75% -91.99% 24.96% 37.35% -1.15% -67.27%
Free Cash Flow Firm Growth		 -94.57% 121.17% 215.03% -5,359.42% -816.02% -120.50% -66.88% 183.54% 69.87% -1,250.67% -661.12%
Invested Capital Growth		 -688.11% -145.07% -225.40% 458.55% -15.26% -294.06% -87.44% -321.02% 16.05% 45.72% 81.80%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Q/Q Growth		 -97.85% 68.23% -166.79% 66.47% -869.96% 37.60% 61.99% 12.23% -17.65% -16.14% 21.70%
EBIT Q/Q Growth		 -97.46% 68.09% -165.23% 66.46% -869.59% 37.62% 61.85% 12.15% -15.36% -18.15% 22.63%
NOPAT Q/Q Growth		 -6.50% -10.24% 13.10% 20.50% -265.26% 40.58% 58.51% -36.13% 39.08% -15.89% 7.88%
Net Income Q/Q Growth		 -86.85% 61.28% -123.17% 57.61% -611.48% 35.69% 63.34% 15.08% -20.95% -20.21% 18.47%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -115.38% 68.90% 16.33% -422.09% 25.48% 41.10% 16.22% -104.06% 37.79% 4.90% -38.54%
Free Cash Flow Firm Q/Q Growth		 1,660.66% 58.83% 145.24% -189.81% -104.69% 95.45% 496.24% 126.50% -173.81% -103.88% -64.61%
Invested Capital Q/Q Growth		 -1,146.67% 55.22% -153.12% 147.08% -315.98% -53.10% -20.40% 44.49% 17.96% 1.00% 59.64%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,081.56% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -911.88% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,084.06% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,054.06% 0.00%
Tax Burden Percent		 100.00% 105.06% 99.90% 100.00% 96.85% 100.00% 99.96% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.50% 116.08% 102.72% 129.70% 98.27% 98.10% 94.31% 91.16% 95.57% 97.23% 102.46%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -20,237.10% 2,764.46% 258.89% -121.82% -391.95% -541.17% -383.74% -150.58% -122.61% -103.80% -87.92%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -1,181.62% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -16.96% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -16.49% 0.00%
Return on Common Equity (ROCE)		 599,605.59% 14,788.74% 299.73% -85.89% -320.71% -437.12% -336.23% -150.58% -122.61% -103.80% -87.92%
Return on Equity Simple (ROE_SIMPLE)		 371.32% 0.00% 191.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.10 -3.42 -2.97 -2.36 -8.62 -5.12 -2.13 -2.89 -1.76 -2.04 -1.88
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -638.31% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -86.43% -119.58% 20.01% 8.68% -34.23% -27.35% -5.06% 3.34% -6.40% -8.46% -5.01%
Return On Investment Capital (ROIC_SIMPLE)		 - 235.38% 78.50% -11.15% -60.27% -38.92% -10.61% -21.36% -13.15% -18.19% -6.62%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 488.75% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 523.13% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,011.88% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.43 -1.41 -3.75 -1.26 -12 -7.60 -2.90 -2.55 -2.94 -3.47 -2.68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.42 -1.40 -3.74 -1.26 -12 -7.60 -2.89 -2.53 -2.98 -3.46 -2.71
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 13.65 0.72 1.69 0.76 1.21 2.08 1.74 2.51
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 26.34 0.72 1.69 0.76 1.21 2.08 1.74 2.51
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 53.39 54.20
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 131.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.87 28.21
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.35 -0.47 -0.42 0.07 0.10 0.11 0.07 0.11 0.12 0.14 3.11
Long-Term Debt to Equity		 -0.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -25.17 -3.29 -0.91 -0.88 -1.81 -1.88 -1.96 -1.07 -1.31 -1.45 -1.35
Leverage Ratio		 258.14 -30.67 -2.58 2.32 3.57 3.81 3.42 1.63 1.65 1.89 2.53
Compound Leverage Factor		 259.42 -35.60 -2.65 3.01 3.51 3.74 3.22 1.48 1.58 1.84 2.59
Debt to Total Capital		 -52.76% -89.59% -71.15% 6.26% 9.35% 10.26% 6.80% 10.15% 10.37% 12.47% 75.65%
Short-Term Debt to Total Capital		 0.00% -89.59% -71.15% 6.26% 9.35% 10.26% 6.80% 10.15% 10.37% 12.47% 75.65%
Long-Term Debt to Total Capital		 -52.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 -78.75% -120.06% -39.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 231.51% 309.65% 211.08% 93.74% 90.65% 89.74% 93.20% 89.85% 89.63% 87.53% 24.35%
Debt to EBITDA		 -0.04 -0.12 -0.23 -0.12 -0.07 -0.05 -0.06 -0.05 -0.09 -0.12 -1.84
Net Debt to EBITDA		 0.01 -0.10 -0.20 1.66 0.92 0.73 1.10 0.65 0.97 1.12 0.71
Long-Term Debt to EBITDA		 -0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.09 -0.11 -0.22 -0.11 -0.08 -0.07 -0.07 -0.07 -0.12 -0.16 -2.51
Net Debt to NOPAT		 0.02 -0.09 -0.19 1.51 0.99 0.95 1.45 0.88 1.30 1.51 0.97
Long-Term Debt to NOPAT		 -0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 59.66 71.11 89.39 10.45 -8.11 -6.75 -4.55 -6.93 -6.62 -8.75 -4.98
Noncontrolling Interest Sharing Ratio		 3,062.90% -434.96% -15.77% 29.49% 18.17% 19.23% 12.38% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.28 0.14 0.13 2.01 2.75 2.06 2.66 2.31 2.33 2.13 1.23
Quick Ratio		 0.09 0.01 0.02 1.81 2.49 1.80 2.28 1.97 1.92 1.74 0.71
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 1.13 1.79 4.39 -3.94 -8.07 -0.37 1.45 3.29 -2.43 -4.96 -8.16
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,020.31%
Free Cash Flow to Firm to Interest Expense		 33.14 7.78 43.03 -9.25 -161.36 -4.89 25.51 274.41 -42.64 -83.99 -35.62
Operating Cash Flow to Interest Expense		 -158.12 -7.27 -13.72 -17.15 -108.86 -42.75 -47.12 -456.75 -59.82 -54.97 -19.62
Operating Cash Flow Less CapEx to Interest Expense		 -158.12 -7.27 -13.72 -17.15 -108.86 -42.75 -47.12 -456.75 -59.82 -54.97 -19.90
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.88
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.61 -1.62 -4.09 1.93 -4.16 -6.37 -7.67 -4.26 -3.49 -3.46 -1.40
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.07 -0.07
Increase / (Decrease) in Invested Capital		 -4.23 -5.21 -7.36 1.58 -0.55 -4.76 -3.58 -6.19 0.67 2.91 6.28
Enterprise Value (EV)		 2,045 2,046 3,185 253 -7.77 1.72 -12 -1.66 9.48 3.80 9.03
Market Capitalization		 2,043 2,043 3,181 271 9.35 20 14 15 25 17 17
Book Value per Share		 ($1.88) ($0.99) ($1,366.14) $39.73 $8.23 $2.66 $4.21 $0.81 $0.82 $0.62 $0.44
Tangible Book Value per Share		 ($5.34) ($3.15) ($3,019.00) $20.58 $8.23 $2.66 $4.21 $0.81 $0.82 $0.62 $0.44
Total Capital		 -2.21 -1.45 -3.78 21 14 13 20 14 13 11 28
Total Debt		 1.17 1.30 2.69 1.33 1.34 1.35 1.36 1.38 1.39 1.40 21
Total Long-Term Debt		 1.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.23 1.13 2.38 -18 -17 -18 -26 -16 -16 -13 -8.32
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -13 -11 -13 -7.22 -4.17 -6.68 -7.98 -4.58 -3.82 -3.79 -1.82
Debt-free Net Working Capital (DFNWC)		 -11 -11 -13 12 14 13 20 13 13 11 28
Net Working Capital (NWC)		 -11 -12 -16 11 13 12 18 12 12 9.50 6.50
Net Nonoperating Expense (NNE)		 1.35 -1.69 0.88 -0.73 2.97 2.33 0.61 -0.57 1.04 1.33 0.87
Net Nonoperating Obligations (NNO)		 -0.23 1.13 2.38 -18 -17 -18 -26 -16 -16 -13 -8.32
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.00 0.00 0.01 0.00 0.01 0.01 -0.04 0.01 -0.03
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,184.06% -567.50%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,405.63% 8,748.75%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,968.13% 2,031.25%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1,344.00) ($305,226.00) ($664.20) ($3.30) ($7.71) ($4.64) ($0.25) ($0.15) ($0.19) ($0.23) ($0.17)
Adjusted Weighted Average Basic Shares Outstanding		 4.13K 6.00 5.84K 499.30K 1.58M 1.61M 11.15M 15.54M 14.74M 14.38M 15.97M
Adjusted Diluted Earnings per Share		 $0.00 ($305,226.00) $0.00 $0.00 $0.00 ($4.64) $0.00 $0.00 $0.00 ($0.23) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 7.60K 10.30K 586.89K 1.41M 4.43M 17.01M 15.08M 14.62M 15.81M 15.82M 15.91M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($305,226.00) $0.00 $0.00 $0.00 ($4.64) $0.00 $0.00 $0.00 ($0.23) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 7.60K 10.30K 586.89K 1.41M 4.43M 17.01M 15.08M 14.62M 15.81M 15.82M 15.91M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.10 -3.42 -2.97 -2.36 -1.83 -5.12 -2.13 -2.89 -1.76 -2.04 -1.88
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -638.31% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,054.06% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -130.15 -6.14 -36.72 -2.95 -243.56 -101.29 -50.84 -212.08 -51.51 -58.80 -11.72
NOPAT to Interest Expense		 -91.12 -14.85 -29.10 -5.54 -172.38 -68.29 -37.28 -241.09 -30.92 -34.62 -8.22
EBIT Less CapEx to Interest Expense		 -130.15 -6.14 -36.72 -2.95 -243.56 -101.29 -50.84 -212.08 -51.51 -58.80 -12.00
NOPAT Less CapEx to Interest Expense		 -91.12 -14.85 -29.10 -5.54 -172.38 -68.29 -37.28 -241.09 -30.92 -34.62 -8.50
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -28.40% -30.69%

Financials Breakdown Chart

Key Financial Trends

Allarity Therapeutics (NASDAQ: ALLR) remains a development-stage biotech with no product revenue, and the latest quarter shows a company still heavily dependent on financing to sustain operations. The overall trend over the last several years is mixed: operating losses have come down from the extreme levels seen in 2024, but the balance sheet is still thin and heavily leveraged relative to cash flow generation.

  • Cash and equivalents rose sharply to $19.8 million in Q1 2026 from $16.9 million in Q3 2025, helped by financing activity.
  • The company ended Q1 2026 with $34.5 million in total current assets, supported by $10.0 million in restricted cash.
  • Net loss improved to $2.75 million in Q1 2026 from $3.37 million in Q4 2025 and $11.59 million in Q3 2024, showing a much leaner cost structure than last year’s peak burn period.
  • Operating expenses fell to $2.71 million in Q1 2026 from $3.24 million in Q4 2025 and well below the $12.31 million spike in Q3 2024, when impairment charges hit results.
  • Research and development spending declined to $1.30 million in Q1 2026, down from $1.67 million in Q4 2025, suggesting tighter spending discipline.
  • The company generated $15.2 million of net cash improvement in Q1 2026, largely due to $20.0 million in debt issuance.
  • There is still no revenue, so ALLR remains entirely dependent on financing and future clinical or licensing success.
  • Current liabilities remain elevated at $28.0 million, including $21.5 million of short-term debt.
  • Working capital is still negative: current assets of $34.5 million versus current liabilities of $28.0 million leaves only a modest cushion, and that cushion is supported by restricted cash.
  • The company continued to post negative operating cash flow of $4.5 million in Q1 2026, which means it is still burning cash from core operations.

Looking at the broader trend, Allarity’s operating profile has improved from the worst point in 2024, when quarterly losses and non-cash charges were far larger. However, the company has also relied on repeated share issuance and debt to fund operations, which can be dilutive and adds financial risk. The latest quarter suggests management has lowered the burn rate, but without revenue, the investment case still depends on future pipeline progress and capital market access.

Bottom line: ALLR’s near-term financial trend is better than it was a year ago, but the company remains speculative. Investors should focus on whether cash preservation continues and whether upcoming clinical or business updates can justify the current funding mix.

07/26/26 08:24 PM ETAI Generated. May Contain Errors.

Allarity Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Allarity Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Allarity Therapeutics' net income appears to be on a downward trend, with a most recent value of -$11.23 million in 2025, falling from -$13.23 million in 2020. The previous period was -$24.52 million in 2024. See Allarity Therapeutics' forecast for analyst expectations on what's next for the company.

Allarity Therapeutics' total operating income in 2025 was -$12.61 million, based on the following breakdown:
  • Total Gross Profit: $320 thousand
  • Total Operating Expenses: $12.93 million

Over the last 5 years, Allarity Therapeutics' total revenue changed from $0.00 in 2020 to $320 thousand in 2025, a change of 32,000,000.0%.

Allarity Therapeutics' total liabilities were at $8.43 million at the end of 2025, a 22.2% decrease from 2024, and a 6.0% decrease since 2020.

In the past 5 years, Allarity Therapeutics' cash and equivalents has ranged from $166 thousand in 2023 to $19.56 million in 2021, and is currently $14.69 million as of their latest financial filing in 2025.

Over the last 5 years, Allarity Therapeutics' book value per share changed from 7.49 in 2020 to 0.62 in 2025, a change of -91.7%.


Related Companies

Financial statements for NASDAQ:ALLR last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The pact that ran the world and dollar just expired
In 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...
Golden Portfolio | Sponsoredtc pixel
Control 100 shares without spending thousands of dollars
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
BlackRock's $2.8B Clue (most investors missed)
BlackRock's new fund on the emerging financial grid hit 2.8 billion in assets in just three months, according ...
Awesomely | Sponsoredtc pixel
August 6 could be a BIG day for one AI company
One AI company's revenue has surged 757 percent in the past year, earning it an A rating from Louis Navellier'...
InvestorPlace | Sponsoredtc pixel
This tiny piece of glass could be bigger than GPUs
Jensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...
Brownstone Research | Sponsoredtc pixel